www.septerna.com/Healthcare / BioTech & PharmaFounded: 2022Funding to Date: $225MM
Septerna is a biochemical drug discovery company. With GPCR scientists, Septerna is focused on researching G protein receptors to develop new medicines in the pharmacology field. The company also features drug-screening technology, modular assemblies, and Silico molecule screening. Septerna was founded by Arthur Christopoulos, Jeffrey Finer, Patrick Sexton, and Robert Lefkowitz in 2022 and is headquartered in San Francisco, CA.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
07/11/2023 | Series B | $150MM | $xx.xx | $313.42MM | Bvf Partners, Casdin Capital, Catalio Capital Management, Deep Track Capital, Direhaus Capital Management, Goldman Sachs Asset Management, Invus, Logos Capital, Mirae Asset Financial Group, Ra Capital Management, Samsara Biocapital, Soleus Capital, Third Rock Ventures, Vertex Ventures Hc, Woodline Partners Lp | |
Price per Share
$xx.xx
Shares Outstanding
121,657,452
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Bvf Partners, Casdin Capital, Catalio Capital Management, Deep Track Capital, Direhaus Capital Management, Goldman Sachs Asset Management, Invus, Logos Capital, Mirae Asset Financial Group, Ra Capital Management, Samsara Biocapital, Soleus Capital, Third Rock Ventures, Vertex Ventures Hc, Woodline Partners Lp
|
||||||
01/27/2022 | Series A | $75MM | $xx.xx | $150MM | Bvf Partners, Casdin Capital, Catalio Capital Management, Invus Financial Advisors, Logos Capital, Samsara Biocapital, Third Rock Ventures | |
Price per Share
$xx.xx
Shares Outstanding
75,000,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Bvf Partners, Casdin Capital, Catalio Capital Management, Invus Financial Advisors, Logos Capital, Samsara Biocapital, Third Rock Ventures
|